Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
SentinelOne CEO Tomer Weingarten disposes of 527,368 shares worth $13.32 million

SentinelOne CEO Tomer Weingarten disposes of 527,368 shares worth $13.32 million

BitgetBitget2026/10/06 23:08

SentinelOne President, CEO, Director Tomer Weingarten sold 527,368 Class A shares on Oct. 5, 2026 at USD 25.2642. He converted 500,000 Class B shares into 500,000 Class A shares at USD 9.74 on the same day. Directly held Class A stake ended at 1,717,510 shares. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SentinelOne Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001866222-26-000043), on October 06, 2026, and is solely responsible for the information contained therein.

  • SentinelOne President, CEO, Director Tomer Weingarten sold 527,368 Class A shares on Oct. 5, 2026 at USD 25.2642.
  • He converted 500,000 Class B shares into 500,000 Class A shares at USD 9.74 on the same day.
  • Directly held Class A stake ended at 1,717,510 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SentinelOne Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001866222-26-000043), on October 06, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)

路透社•2026/10/09 04:26
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals

Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low

UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.

智通财经•2026/10/09 03:53